AgingResearch.NewsJoin free

Caribou Biosciences

CompanyUnited States

Caribou Biosciences develops one asset, in phase 1 (CB-011 in relapsed refractory multiple myeloma). Mostly cell therapy acting on TNFRSF17; based in the United States.

1
Asset
Furthest stage
Phase 1
1
Trial
1
Signal

Pipeline

1

  • CB-011

    Gene-edited allogeneic CAR T cells target BCMA-expressing myeloma cells.

    Phase 1, Cell therapy, TNFRSF17, relapsed refractory multiple myeloma

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • Signals1
  • Similar companies5

Intelligence